Tecentriq approved for a type of NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

TECENTRIQ (atezolizumab) received FDA approval for the treatment of people with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities. The agent is sponsored by Genentech, a member of the Roche Group....

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login